Figure 1.

Osteogenic Differentiation and Expression Patterns of CDR1as in HPASMCs during Hypoxia (Hyp)

(A) HPASMCs were treated with pro-calcifying media containing 2.5 mM inorganic phosphate, and cell calcification was assessed by ARS staining. (B) Immunofluorescence analysis of Runx2 in HPASMCs from normoxia (Nor) and Hyp. Scale bar, 50 μm. (C) Genomic source of CDR1as. (D) Relative expression of CDR1as in Hyp was increased as determined by qPCR analysis. (E) FISH assay was performed to detect CDR1as distribution and expression in cultured cells. Scale bar, 25 μm. (F) The expression level of CDR1as in small interfering RNA (siRNA)- and negative control (siNC)-transfected cells. ∗p < 0.05, ∗∗p < 0.01. All tests were performed at least three times, and the values are presented as the mean ± SEM.